Clinical Trials Sponsored by Intervene Immune, Inc.

Total 118 results

Intervene Immune, Inc.

Recruiting

Thymus Regeneration, Immunorestoration, and Insulin Mitigation Extension Trial (TRIIM-X)

Immunosenescence | Epigenetic Aging

United States
Intervene, Inc.

Recruiting

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System (INFINITE-OUS)

Chronic Venous Insufficiency

New Zealand, Australia, Canada
Intervene, Inc.

Terminated

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System - INFINITE-US (INFINITE-US)

Chronic Venous Insufficiency (CVI) | Deep Vein Reflux

United States
Intervene, Inc.

Withdrawn

Investigation of Femoropopliteal In Situ Valve Formation With the InterVene System-Canada

Chronic Venous Insufficiency
Intervene, Inc.

Terminated

A Feasibility Study of the ReLeaf Catheter System (ReLeaf)

Chronic Venous Insufficiency

New Zealand
Immune Biosolutions Inc

Completed

Study in Adults to Assess the Safety and Efficacy of Inhaled IBIO123, for Post-exposure Prophylaxis of COVID-19

COVID-19

South Africa, Ukraine
Immune Biosolutions Inc

Completed

Phase 1/2 Study to Evaluate the Efficacy and Safety of Inhaled IBIO123 in Participants With Mild to Moderate COVID-19 Illness

COVID-19

South Africa, Brazil
Immune Biosolutions Inc

Completed

Phase 1&2 Study to Evaluate the Safety & Efficacy of Inhaled IBIO123 in Severe COVID-19 Illness

COVID-19

Ukraine, South Africa
Natural Immune Systems Inc

Recruiting

Clinical Proof-of-concept Study on Immune Surveillance and Alertness

Immune Surveillance

United States
Natural Immune Systems Inc

Recruiting

Antioxidant Bioavailability

Pharmacokinetics

United States
Immune Design
Genentech, Inc.

Terminated

Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002)

Sarcoma | Myxoid/Round Cell Liposarcoma | Liposarcoma | Synovial Sarcoma | Recurrent Adult Soft Tissue Sarcoma | Metastatic Sarcoma | Locally Advanced Sarcoma

United States
Natural Immune Systems Inc

Completed

Nutraceutical Support of Fatigue Reduction, Improved Physical, Mental & Cognitive Function and Mitochondrial Function

Fatigue

United States
Natural Immune Systems Inc

Completed

Evaluation of Activity Levels, Inflammatory Markers, and Overall Wellness. (114-012)

Range of Motion

United States
Natural Immune Systems Inc

Completed

CytoQuel: Clinical Documentation on Effects on Chronic Pain, Wellness, and Reduction of Inflammatory Markers

Pain

United States
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias (RUBY-4)

Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura | Cold Agglutinin Disease | Warm Autoimmune Hemolytic Anemia

United States, Canada, Australia, Turkey, United Kingdom
Alpine Immune Sciences, Inc.

Recruiting

An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases (RUBY-3)

Lupus Nephritis | Immunoglobulin A Nephropathy | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Membranous Nephropathy

United States, Australia, Korea, Republic of
Noile-Immune Biotech, Inc

Recruiting

Study of NIB101 in Participants With Advanced Solid Tumors

Solid Tumor

Japan
Natural Immune Systems Inc

Recruiting

Immunological Effect of Increasing Doses of Natural Peptide

Pharmacokinetics

United States
Natural Immune Systems Inc

Recruiting

Clinical Study on Rapid Antioxidant Protection and Immune Modulating Effects.

Pharmacokinetics

United States
Immune Response BioPharma, Inc.

Not yet recruiting

A Study of NeuroVax™, a Novel Therapeutic TCR Peptide Vaccine for Pediatric Multiple Sclerosis

Multiple Sclerosis

United States
Alpine Immune Sciences, Inc.

Active, not recruiting

ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus (Synergy)

Systemic Lupus Erythematosus

United States, France, Hungary, Poland, Puerto Rico, Spain, Taiwan
Alpine Immune Sciences, Inc.

Terminated

ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD (Balance)

Graft Vs Host Disease

United States
Immune Response BioPharma, Inc.

Unknown

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

HIV/AIDS

United States
Natural Immune Systems Inc

Completed

Efficacy of Jobelyn™ Consumption on Hemoglobin Levels in a Borderline Anemic Population

Anemia

United States
Natural Immune Systems Inc

Not yet recruiting

Phospholipids as Nutritional Support for Reduction of Anxiety

Anxiety
Natural Immune Systems Inc

Recruiting

Clinical Proof-of-concept Study on Rapid Immune Modulating Effects

Immune Surveillance

United States
Alpine Immune Sciences, Inc.

Terminated

An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies (NEON-1)

Lymphoma | Advanced Solid Tumor

United States, Australia
Alpine Immune Sciences, Inc.

Completed

A Study of ALPN-303 in Adult Healthy Volunteers (RUBY-1)

Healthy Volunteers

Australia
Natural Immune Systems Inc

Completed

Evaluation of Hydration Status When Consuming Alkaline Water Compared to Reverse Osmosis Purified Water.

Hydration

United States
Natural Immune Systems Inc

Completed

Acute Effects of an Herbal Tea on Immune Surveillance and Activation.

Active Immune Response

United States
Natural Immune Systems Inc

Completed

Effects of Topical Cream for Pain Relief

Chronic Pain

United States
Alpine Immune Sciences, Inc.

Completed

Cell Surface Marker Expression in Autoimmune Diseases (CASCADE)

Multiple Sclerosis | Systemic Lupus Erythematosus | Systemic Sclerosis | Crohn's Disease | Ulcerative Colitis | Sjogren's Syndrome | Inflammatory Myositis

Canada
Natural Immune Systems Inc

Unknown

Evaluation of Plant-based Nutritional Products on Stem Cells

Stem Cell Mobilization | Hematopoietic Stem Cell Mobilization | Stem Cell Homing

United States
Natural Immune Systems Inc

Completed

Alkaline Ionized Water: Sports Recovery and Inflammation Management

Sports Recovery

United States
Immune Response BioPharma, Inc.

Unknown

REMUNE + AMPLIVAX IR103 HIV/AIDS Phase III Safety & Efficacy Study (RAISE)

HIV

United States
Immune-Onc Therapeutics

Active, not recruiting

Dose-Escalation and Dose-Expansion Study of IO-202 and IO-202+Pembrolizumab in Solid Tumors

Solid Tumor, Adult

United States
Immune-Onc Therapeutics

Recruiting

Dose Confirmation and Dose Expansion Phase 1 Study of IO-108 and IO-108 + Anti-PD-1 in Solid Tumors

Advanced Solid Tumor

China
Inmune Bio, Inc.

Recruiting

Study of INKmune in Patients With mCRPC (CaRe Prostate) (CaRe)

Cancer | Metastatic Castration-resistant Prostate Cancer | mCRPC

United States
Inmune Bio, Inc.

Recruiting

A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation (MINDFuL)

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies | Mild Cognitive Impairment

Australia, Canada, United Kingdom, Poland, Germany
Aimmune Therapeutics, Inc.

Completed

Longer-term Study of AR101 in Subjects Who Participated in a Prior AR101 Study (ARC008)

Peanut Allergy

United States, Canada, Spain, Netherlands, Germany, United Kingdom, Ireland, Sweden, France, Italy
Aimmune Therapeutics, Inc.

Terminated

Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy

Hen Egg Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Real-World AR101 Market-Supporting Experience Study in Peanut-Allergic Children (RAMSES) (RAMSES)

Peanut Allergy

United States, Canada
Aimmune Therapeutics, Inc.

Terminated

Real World, Open Label, QOL Assessment of Peanut Immunotherapy AR101 in Children and Adolescents

Peanut Allergy

Spain
Timmune Biotech Inc.

Unknown

Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy

Non-hodgkin Lymphoma,B Cell

China
Inmune Bio, Inc.

Recruiting

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Mental Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Neurocognitive Disorders | Neurodegenerative Diseases | Dementia | Alzheimer Disease | Tauopathies

Australia, Canada
Inmune Bio, Inc.

Terminated

A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL)

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Cancer | AML | MDS-EB

United Kingdom, Greece
Inmune Bio, Inc.

Terminated

INB03 for the Treatment of Pulmonary Complications From COVID-19

COVID-19

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT (ARC001)

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

Peanut Allergy

United States
Aimmune Therapeutics, Inc.

Completed

AR101 Real-World Open-Label Extension Study

Peanut Allergy

United States, Canada

Clinical Trials Sponsored by Intervene Immune, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations